Q-omics provides the consensus-scored IGKV6D-41 profile across patient tissues and cancer cell-line models. IGKV6D-41 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, IGKV6D-41 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, IGKV6D-41 RNA expression shows 6,233 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight UCEC, COAD, and BRCA as cancer lineages where IGKV6D-41 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGKV6D-41 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGKV6D-41 survival associations across molecular data types. IGKV6D-41 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGKV6D-41 RNA expression–survival associations across cancer types. High IGKV6D-41 expression shows unfavorable associations in UVM and DLBC, but favorable associations in UCEC, BRCA, HNSC and BLCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for IGKV6D-41 RNA expression.
This table summarizes IGKV6D-41 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGKV6D-41. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGKV6D-41 shows lower tumor expression in COAD, BRCA, LIHC and READ and higher tumor expression in KIRC and LUAD. The COAD box plot shows higher IGKV6D-41 RNA expression in normal versus tumor tissue (log2 FC = −0.850, t-test p < 0.001).
This table shows molecular features associated with IGKV6D-41 in patient tissues and cancer cell lines. In patient samples, IGKV6D-41 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
